Skip to main content
Explore URMC

menu

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Research Question:
Does the drug DSP-7888 help patients with glioblastoma?

Basic Study Information

Purpose:
This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Boston Biomedical
Phone: (844) 904-7088
Email: US110@xfactorbbi.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search